1,637 Shares in Medpace Holdings, Inc. $MEDP Purchased by Sierra Summit Advisors LLC

Sierra Summit Advisors LLC purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,637 shares of the company’s stock, valued at approximately $919,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in MEDP. Optiver Holding B.V. purchased a new position in Medpace during the third quarter worth about $27,000. Geneos Wealth Management Inc. boosted its holdings in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. purchased a new position in Medpace during the fourth quarter worth about $30,000. Elyxium Wealth LLC purchased a new position in Medpace during the fourth quarter worth about $30,000. Finally, Quarry LP purchased a new position in Medpace during the third quarter worth about $35,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Rosen, Pomerantz, Schall, The Gross Law Firm, and Bleichmar Fonti & Auld, announced or promoted class action claims against Medpace Holdings, Inc. (MEDP), keeping legal overhang in focus for shareholders. Article Title
• Negative Sentiment: The lawsuits allege investor harm tied to disclosures about cancellation rates and other operating metrics, which could raise litigation costs and uncertainty around management credibility. Article Title
• Negative Sentiment: The repeated reminders about June 2026 filing deadlines suggest the legal situation is still active and could remain a drag on sentiment in the near term. Article Title
• Neutral Sentiment: Separately, Medpace shareholders approved governance changes enhancing voting rights at the company’s annual meeting, but this appears less immediately impactful than the litigation headlines. Article Title

Insider Activity

In other news, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the sale, the president owned 15,000 shares of the company’s stock, valued at $6,829,500. The trade was a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 20.50% of the stock is currently owned by company insiders.

Medpace Stock Up 0.5%

NASDAQ MEDP opened at $421.87 on Thursday. The company’s 50 day moving average is $460.55 and its 200-day moving average is $521.15. Medpace Holdings, Inc. has a 12-month low of $287.17 and a 12-month high of $628.92. The firm has a market cap of $12.05 billion, a P/E ratio of 26.52, a price-to-earnings-growth ratio of 2.13 and a beta of 1.19.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. During the same quarter in the previous year, the firm posted $3.67 earnings per share. The company’s quarterly revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts expect that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on MEDP. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a report on Friday, February 13th. Royal Bank Of Canada lowered their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Leerink Partners lowered their price objective on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 11th. Finally, Truist Financial lowered their price objective on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. Four equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $467.08.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.